Search for a command to run...
GKB Ophthalmics Ltd. demonstrates moderate revenue growth but faces significant profitability challenges with negative margins and returns. Among its peers, Poly Medicure Ltd. stands out as a strong performer in profitability and growth metrics, while several companies like Nureca Ltd. and GKB itself exhibit financial weaknesses. Investors should cautiously evaluate GKB, considering its growth potential against profitability risks.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
GKB | ₹78.98 | ₹39.81Cr | -6.52 | -6.32% | 0.28 |
POLYMED | ₹2,072.30 | ₹20,997.79Cr | 63.37 | 20.37% | 0.06 |
LAXMIDENTL | ₹340.30 | ₹1,870.36Cr | 100.52 | 21.79% | 0.99 |
Prevest Denpro Ltd. | ₹569.55 | ₹683.63Cr | 37.56 | 25.24% | - |
Hemant Surgical Industries Ltd. | ₹297.80 | ₹310.90Cr | 38.24 | - | - |
NURECA | ₹241.55 | ₹241.55Cr | -184.25 | -1.06% | 0.00 |
Raaj Medisafe India Ltd. | ₹84.59 | ₹111.77Cr | 18.23 | - | - |